Last 0.54 GBp
Change Today 0.00 / 0.00%
Volume 0.0
AKT On Other Exchanges
Symbol
Exchange
London
Munich
OTC US
As of 12:00 PM 03/28/14 All times are local (Market data is delayed by at least 15 minutes).

ark therapeutics group plc (AKT) Snapshot

Open
--
Previous Close
0.54 GBp
Day High
--
Day Low
--
52 Week High
03/21/14 - 0.58 GBp
52 Week Low
11/6/13 - 0.28 GBp
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
-0.0040 GBp
Shares Outstanding
209.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARK THERAPEUTICS GROUP PLC (AKT)

Related News

No related news articles were found.

ark therapeutics group plc (AKT) Related Businessweek News

No Related Businessweek News Found

ark therapeutics group plc (AKT) Details

Ark Therapeutics Group plc does not have significant operations. Prior to March 15, 2013, the company was engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. Ark Therapeutics Group plc is based in London, the United Kingdom.

ark therapeutics group plc (AKT) Top Compensated Officers

Co-Founder
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Company Secretary and Non-Executive Director
Total Annual Compensation: --
Head of Business Development
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

ark therapeutics group plc (AKT) Key Developments

Ark Therapeutics Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014; Announces Registered Office Address Change

Ark Therapeutics Group plc reported unaudited consolidated earnings results for the six months ended June 30, 2014. For the period, the company reported operating loss of £483,000 against profit of £1,396,000 a year ago. Loss on ordinary activities before taxation was £482,000 against profit of £1,397,000 a year ago. Loss on ordinary activities after taxation was £482,000 against profit of £6,022,000 a year ago. Loss on ordinary activities after taxation, being retained loss for the period was £482,000 or 0.2 pence per diluted share against profit of £1,397,000 or 0.6 pence per diluted share a year ago. Net cash used in operating activities was £99,000 against £1,391,000 a year ago. The company also announced that it has changed its registered office to 11 Staple Inn, London WC1V 7QH with immediate effect.

Ark Therapeutics Group plc Announces Board Changes

Ark Therapeutics Group plc announced the retirement of Charles Spicer as a Non-Executive Director with effect from the Annual General Meeting. The Company also announced the appointment of Sue Steven as a Non-Executive Director of the company with effect from June 30, 2014. Mrs. Steven has worked with the company for over 10 years. Mrs. Steven currently acts as the Company Secretary and will continue in that role alongside her directorship. Prior to joining the company, Mrs. Steven held a number of managerial roles within a wide range of sectors, including legal, 3G mobile communications, computing and animal healthcare.

Ark Therapeutics Group plc, Annual General Meeting, Jun 30, 2014

Ark Therapeutics Group plc, Annual General Meeting, Jun 30, 2014., at 14:30 GMT Standard Time. Location: The offices of Ashurst LLP, Broadwalk House.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKT:LN 0.54 GBp 0.00

AKT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKT.
View Industry Companies
 

Industry Analysis

AKT

Industry Average

Valuation AKT Industry Range
No financial data is available for AKT.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARK THERAPEUTICS GROUP PLC, please visit www.arktherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.